On 31st October 2014 Cancer52 submitted its response to the NHS England Consultation: Proposals for a sustainable Cancer Drugs Fund.
You can read a summary of our submission here.
Our key calls are for
- a wider debate, just as called for by NICE, to create a consensus on what we need to enable access to new medicines for those with rare and less common cancers
- a system that:
- includes new definitions for both 'unmet need' and 'rarity'
- gives appropriate weight in re-evaluation to the needs of patients with cancers that have extremely high mortality rates or where there are limited treatment options
- is transparent
- is clinically, not financially driven
If you would like to read the Cancer52's response to the CDF (October 2014) consultation in full, please click here.